September 7,2022 — Neurelis, Inc., issued a press release, which is summarized as follows:
Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates a significant increase in time between seizure clusters treated with VALTOCO® (diazepam nasal spray) CIV. Epilepsia is the world’s leading, peer-reviewed journal that publishes original scientific research on the multiple clinical and investigational aspects of epilepsy.
“The most exciting finding of the study is the robustness of the signal in the cluster-interval data” said co-author and Assistant Professor of Neurology at Harvard Medical School, Jurriaan Peters, MD. “The results consistently showed a clinical and statistical increase in the time between use of intranasal diazepam, VALTOCO, over time.”
Of the 163 patients enrolled in the 12-month study, an increase in SEIVAL was noted from the first three months of the trial (Period 1) to all subsequent periods. A subset of patients from a 12-month safety study demonstrated the mean SEIVAL increased significantly, from 13.9 days in Period 1 (day 1-90) to 26.8 days in Period 4 (day 271-360), an average increase of 12.9 days between seizure clusters treated with VALTOCO.
Original website Link: https://www.neurelis.com/study-published-epilepsia-shows-significant-prolongation-time-intervals-between-seizure-clusters